Epidermal growth factor receptor (EGFR) inhibition by erlotinib blocks tumor cell growth and initiates apoptosis in EGFR-overexpressing tumor cells.23 Approximately 55% to 98% of advanced epithelial ovarian carcinomas have been found to overexpress EGFR.24 A phase III trial including 14 patients with mucinous ovarian carcinoma exhibited no overall or histological subtype-based improvement in median progression-free survival or overall survival.25 Tumor EGFR status was not a criterion for selection of patients in this trial. The gene discussed is EGFR; the disease is neoplasm.